Three-Drug Combo Promising Against High-Risk CLL Three-Drug Combo Promising Against High-Risk CLL

The combination of obinutuzumab, ibrutinib, and venetoclax was associated with a high complete response rate in patients with high-risk chronic lymphocytic leukemia, a phase 2 trial finds.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Alert Source Type: news